Overview

  • Product nameAnti-Apolipoprotein E antibody [EP1374Y]See all Apolipoprotein E primary antibodies ...
  • Description
    Rabbit monoclonal [EP1374Y] to Apolipoprotein E
  • Tested applicationsWB, IP, IHC-P, ICC/IF more details
  • Species reactivity
    Reacts with: Human

    Does not react with

    Mouse, Rat
  • Immunogen

    A synthetic peptide corresponding to residues near the C-term of human apolipoprotein E.

  • Positive control
    • Human serum; human normal liver tissue; HepG2 cells.
  • General notesProduced under U.S. Patent No. 5,675,063.

Applications

Our Abpromise guarantee covers the use of ab52607 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
WB 1/1000 - 1/10000. Detects a band of approximately 36 kDa (predicted molecular weight: 36 kDa).
IP 1/100.
IHC-P 1/100 - 1/250. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ICC/IF 1/250 - 1/500.

Target

  • FunctionMediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.
  • Tissue specificityOccurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.
  • Involvement in diseaseDefects in APOE are a cause of hyperlipoproteinemia type 3 (HLPP3) [MIM:107741]; also known as familial dysbetalipoproteinemia. Individuals with HLPP3 are clinically characterized by xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of HLPP3 have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD.
    Genetic variations in APOE are associated with Alzheimer disease type 2 (AD2) [MIM:104310]. It is a late-onset neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. Note=The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease. Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known.
    Defects in APOE are a cause of sea-blue histiocyte disease (SBHD) [MIM:269600]; also known as sea-blue histiocytosis. This disorder is characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses.
    Defects in APOE are a cause of lipoprotein glomerulopathy (LPG) [MIM:611771]. LPG is an uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries. It mainly affects people of Japanese and Chinese origin. The disorder has rarely been described in Caucasians.
  • Sequence similaritiesBelongs to the apolipoprotein A1/A4/E family.
  • Post-translational
    modifications
    Synthesized with the sialic acid attached by O-glycosidic linkage and is subsequently desialylated in plasma. O-glycosylated with core 1 or possibly core 8 glycans. Thr-307 is a minor glycosylation site compared to Ser-308.
    Glycated in plasma VLDL of normal subjects, and of hyperglycemic diabetic patients at a higher level (2-3 fold).
    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localizationSecreted.
  • Target information above from: UniProt accession P02649 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
    • AD2 antibody
    • Alzheimer disease 2 antibody
    • Apo E antibody
    • Apo-E antibody
    • ApoE antibody
    • APOE_HUMAN antibody
    • APOEA antibody
    • Apolipoprotein E antibody
    • Apolipoprotein E3 antibody
    • ApolipoproteinE antibody
    • Apoprotein antibody
    • LDLCQ5 antibody
    • LPG antibody
    • MGC1571 antibody
    see all

Anti-Apolipoprotein E antibody [EP1374Y] images

  • Anti-Apolipoprotein E antibody [EP1374Y] (ab52607) at 1/20000 dilution + Human serum at 10 µg

    Secondary
    HRP-labelled goat anti-rabbit at 1/2000 dilution

    Predicted band size : 36 kDa
    Observed band size : 36 kDa
  • Immunohistochemical analysis of paraffin-embedded human normal liver using ab52607 at a dilution of 1/100-1/250.
  • Immunofluorescent staining of HepG2 cells using ab52607 at a dilution of 1/250-1/500.

References for Anti-Apolipoprotein E antibody [EP1374Y] (ab52607)

This product has been referenced in:
  • van Beers JJ  et al. The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and ß-actin. Arthritis Rheum 65:69-80 (2013). WB ; Human . Read more (PubMed: 23044660) »
  • Coller KE  et al. Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog 8:e1002466 (2012). ICC/IF . Read more (PubMed: 22241992) »

See all 4 Publications for this product

Product Wall

Application Western blot
Sample Human Cell lysate - whole cell (Mono-Mac 6)
Loading amount 50 µg
Specification Mono-Mac 6
Treatment TO-901317
Gel Running Conditions Reduced Denaturing (8%)
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 0.5% · Temperature: RT°C
Username

Dr. Elizabeth Kilby

Verified customer

Submitted Dec 18 2012

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (THP1 monocyte-derived macrophages)
Specification THP1 monocyte-derived macrophages
Fixative Paraformaldehyde
Permeabilization Yes - 0.25% Triton X-100 in PBS
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: RT°C
Username

Dr. Elizabeth Kilby

Verified customer

Submitted Nov 02 2012

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"